BICYCLE THERAPEUTICS PLC
About BICYCLE THERAPEUTICS PLC
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $72.6M
- Net income
- -$219.0M
- Total assets
- $717.6M
- Market cap
- $293.2M
- Operating margin
- -595.0%
- Net margin
- -479.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $35.3M
- Operating expenses
- $245.1M
- Operating income
- -$209.9M
- Income tax
- -$4.8M
- Net income
- -$169.0M
- EPS (basic)
- $-2.90
- EPS (diluted)
- $-2.90
Balance sheet
- Total assets
- $956.9M
- Current assets
- $928.6M
- Total liabilities
- $163.8M
- Current liabilities
- $67.2M
- Shareholders’ equity
- $793.1M
Cash flow
- Operating cash flow
- -$164.7M
- Investing cash flow
- -$1.2M
- Financing cash flow
- $519.8M
- Net cash flow
- $353.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $293.2M
- EPS (diluted)
- $-2.9
- Shares outstanding
- 71.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 23, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $219.0M in FY2025.
- Revenue grew 240% from FY2020 to FY2024.
- Trading 55% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BICYCLE THERAPEUTICS PLC.
Write a review
News about BICYCLE THERAPEUTICS PLC
News & sentiment via Polygon.io
